✦ LIBER ✦

Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease

✍ Scribed by D.J. Taber; E. Ashcraft; G.M. Baillie; S. Berkman; J. Rogers; P.K. Baliga; P.R. Rajagopalan; A. Lin; O. Emovon; F. Afzal; K.D. Chavin

Book ID: 110903998
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 151 KB
Volume: 6
Category: Article
ISSN: 1398-2273
DOI: 10.1111/j.1399-3062.2004.00066.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cytomegalovirus Disease in High-Risk Tra

Cytomegalovirus Disease in High-Risk Transplant Recipients Despite Ganciclovir or Valganciclovir Prophylaxis

✍ Enver Akalin; Vinita Sehgal; Scott Ames; Sabera Hossain; Lisa Daly; Murphy Barba 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Prophylaxis of cytomegalovirus disease i

Prophylaxis of cytomegalovirus disease in high-risk patients

✍ M. Scholz; J. Cinatl; H. W. Doerr 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 813 KB

Impact of Valganciclovir Prophylaxis on

Impact of Valganciclovir Prophylaxis on the Development of Severe Late-Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients

✍ C. Cervera; M. Pineda; L. Linares; M.A. Marcos; C. Esteva; A. Antón; F. Cofán; M 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Oral ganciclovir versus valganciclovir f

Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients

✍ R.L. Brady; K. Green; C. Frei; P. Maxwell 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

Risk of cytomegalovirus disease in high-

Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis

✍ Kalil, Andre C.; Mindru, Cezarina; Botha, Jean F.; Grant, Wendy J.; Mercer, Davi 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB

Increased incidence of cytomegalovirus i

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis

✍ Kevin T. Shiley; Leanne B. Gasink; Todd D. Barton; Patrice Pfeiffenberger; Kim M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

Optimal measures for the prevention of cytomegalovirus (CMV) in high-risk orthotopic liver transplant (OLT) patients are unknown. The charts of high-risk OLT recipients with 12 months of follow-up who were transplanted over a 44-month period were reviewed. The incidence of CMV disease in CMV-seropos